The Motley Fool··Geoffrey SeilerHims & Hers Bets Big on Weight-Loss Drugs as Margins Compress
Hims & Hers raised 2026 revenue guidance to $2.8-3.0B but slashed EBITDA outlook due to margin pressure from branded weight-loss drug pivot.
NVOHIMSearnings missmargin compression